Moneycontrol PRO
HomeNewsBusinessStocksLong Sun Pharma; short Lupin: Emkay

Long Sun Pharma; short Lupin: Emkay

Emkay Global Financial Services has recommended to buy Sun Pharma at Rs 806-808 and sell Lupin at Rs 1422-1424 in anticipation of a reversion in the price ratio, in its research report dated December 22, 2014.

December 30, 2014 / 17:55 IST
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Emkay Global Financial Services' research report

    Strategy

    Buy Sun Pharma (SUNP.IS) @ 806-808 and Sell Lupin (LPC.IS) @ 1422-1424 in anticipation of a reversion in the price ratio. The current price ratio is 0.5671 and the target price ratio is 0.6238. We recommend holding positions with a stop loss placed at 0.5388 on a closing basis. The strategy has to be a rupee neutral strategy.

    Rationale

    "The chart (in the pdf) indicates the normalized spread prevailing between returns of Sun Pharma vis-à-vis Lupin in a one year data window. Since 23 December, 2013, Sun Pharma has surged by around 40% while Lupin has increased by around 56%, resulting into a negative return spread of around 16%. Historically, in the last 1 year, the pair has shown convergence in the range of -19% to -15% on 2 occasions (as shown in chart below). We believe a similar situation to occur", says Emkay Global Financial Services research.

    For all recommendations, click here

    Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

    first published: Dec 30, 2014 05:55 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347